Leading bioscience company, Penn Pharma has completed the first phase of its £12m expansion programme by investing £315k in upgrading the site and improving transport access.

As part of sustained investment in the site, and partly backed by the Welsh Assembly Government's Single Investment Fund, Penn has extended its facilities by 2400m² and completely changed the transport and delivery infrastructure at the company’s Tredegar head quarters.

Darren Hassey, Chief Operating Officer at Penn Pharma said: "The recent developments to the site only add to established offering. By altering the externals of the site and moving the delivery and collection points we have in turn altered the internal factory processes, ensuring the smooth flow of people, process and materials."

The £12m expansion plans are planned to be rolled out throughout the next five years with the company aiming to complete upgrades in keeping with its growth.

Peter George, CEO of Penn Pharma, said, "By heavily investing in our Tredegar site it strengthens our commitment to the local community and as a leading Welsh company we will endeavour to payback the Assembly Governments faith in us by driving sustainable growth and employment."

Penn, founded thirty years ago and based at Tredegar for the past twenty three years, is a highly specialised pharmaceutical company which combines an integrated pharmaceutical development service with low volume clinical and commercial manufacturing. The company has achieved very strong growth in recent years, with customers from many of the world's leading pharmaceutical companies in the UK, EU and USA.